AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Earnings for AbbVie Inc. (ABBV)
Earnings in 2023 (TTM): $6.25 B
According to AbbVie Inc.'s latest financial reports the company's current earnings (TTM) are $6.25 B. The earnings displayed on this page is the company's Pretax Income.
Earnings history of AbbVie Inc.
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2023 | $6.25 B | $4.86 B |
| 2022 | $13.48 B | $11.84 B |
| 2021 | $12.99 B | $11.54 B |
| 2020 | $3.4 B | $4.62 B |
| 2019 | $8.43 B | $7.88 B |
| 2018 | $5.2 B | $5.69 B |
| 2017 | $7.73 B | $5.31 B |
| 2016 | $7.88 B | $5.95 B |
| 2015 | $6.65 B | $5.14 B |
| 2014 | $2.37 B | $1.77 B |
| 2013 | $5.33 B | $4.13 B |
| 2012 | $5.73 B | $5.28 B |
| 2011 | $3.67 B | $3.43 B |
| 2010 | $4.84 B | $4.18 B |
| 2009 | $5.95 B | $4.64 B |